Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.

You may also be interested in...



IMS Health’s Yan Shangjun On China’s Changing Diabetes Market: An Interview With PharmAsia News

IMS Health Inc. Pharma Insight Principal Yan Shangjun sits down with PharmAsia News to talk about the evolution of China’s diabetes market and how opinions of Chinese doctors affect the market.

NICE’s Forxiga Reversal For Diabetes 2 Restricts Treatment Regimens

Reversing a previous stance, NICE has now agreed to recommend BMS/AZ’s Forxiga for diabetes type 2, though questions concerning data on combination regimens led to restrictions.

Merck And Pfizer Make A Late Play For The Diabetes Market

Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel